ArticlemBio2021
Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature.Frontiers in immunology · 2023Pooled it
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.The New England journal of medicine · 2021Trial
- Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.The Journal of clinical investigation · 2020Trial
- Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset.European journal of immunology · 2020Trial
- SARS-CoV-2 Nsp15 facilitates immune evasion and viral replication by limiting multiple host innate immune pathways, including cGAS-STING.The Journal of general virology · 2026Article
- T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.iScience · 2025Article
- Pan-Variant SARS-CoV-2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Dry powder formulations of hyperimmune serum.Drug delivery and translational research · 2025Article
- Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles.The Journal of clinical investigation · 2025Article
- In-depth immunochemical characterization of the serum antibody response using a dual-titration microspot assay.Frontiers in immunology · 2025Article
- TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.Nature communications · 2024Article
- SARS-CoV-2 Nsp15 antagonizes the cGAS-STING-mediated antiviral innate immune responses.bioRxiv : the preprint server for biology · 2024Article
- High-Throughput Screening Assay for Convalescent Sera in COVID-19: Efficacy, Donor Selection, and Variant Neutralization.Microorganisms · 2024Article
- TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.bioRxiv : the preprint server for biology · 2024Article
- AnmBio · 2024Article
- Beluga whale and bottlenose dolphin ACE2 proteins allow cell entry mediated by spike protein from three variants of SARS-CoV-2.Biology letters · 2023Article
- New Sorbicillinoids from the Mangrove Endophytic FungusMarine drugs · 2023Article
- Metagenomics-enabled reverse-genetics assembly and characterization of myotis bat morbillivirus.Nature microbiology · 2023Article
- Single-Virus Fusion Measurements Reveal Multiple Mechanistically Equivalent Pathways for SARS-CoV-2 Entry.Journal of virology · 2023Article
- Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies.Pharmaceutics · 2023Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
32 authors at 3 institutions in 1 country.
Kasopefoluwa Y Oguntuyo *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-7824-2892
Christian S Stevens *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-2472-6984
Chuan Tien HungDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-6899-1312
Satoshi IkegameDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Joshua A AcklinDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Shreyas S KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jillian C CarmichaelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0001-5270-5916
Hsin-Ping ChiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kristopher D AzarmDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Griffin D HaasDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jéromine KlinglerDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Ian BaineDepartment of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Suzanne ArinsburgDepartment of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Juan C BandresDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Mohammed N A SiddiqueyDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.
Robert M SchilkeDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.
Matthew D WoolardDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.
Hongbo ZhangDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.
COVIDAR Argentina Consortium
Andrew J DutyDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Thomas A KrausDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Thomas M MoranDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Domenico TortorellaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jean K LimDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Andrea V GamarnikDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Catarina E HioeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Susan Zolla-PaznerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0002-0750-2666
Stanimir S IvanovDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.
Jeremy P KamilDepartment of Microbiology and Immunology, Louisiana State University Health Science Center Shreveport, Shreveport, Louisiana, USA.ORCID 0000-0001-8422-7656
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4121-776X
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Benhur.Lee@mssm.edu.ORCID 0000-0003-0760-1709
Icahn School of Medicine at Mount Sinai · USLouisiana State University Health Sciences Center Shreveport · USJames J. Peters VA Medical Center · US
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MMSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6MTRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5MHarnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIVR01AI139290 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HIOE, CATARINA E · 2018 to 2022
$4.1MRoles of the UL148 glycoprotein in human cytomegalovirus infectionR01AI116851 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jeremy Phillip Kamil · 2016 to 2026
$3.5MTropism, pathogenicity, and potential for zoonotic spillover of emergent henipa- and henipa-like virusesR01AI123449 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR · 2016 to 2020
$2.7MSUMO and ubiquitin modifications in henipavirus matrix trafficking and functionR01AI125536 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR · 2016 to 2020
$2.1MRegulation of Legionella pneumophila pathogenesis by the central eukaryotic metabolic checkpoint kinase Mechanistic Target of Rapamycin (MTOR)R01AI143839 · NIAID · LOUISIANA STATE UNIV HSC SHREVEPORT · PI IVANOV, STANIMIR STEFANOV · 2019 to 2023
$1.8MHuman Parainfluenza Virus 3 Infection in a Novel Human Lung Tissue ModelR21AI149033 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR, LIM, JEAN KYOU · 2020 to 2021
$463kMetabolic and Immune Consequences of Antibiotic-Related Microbiome Alterations during TB TreatmentR21AI148033 · NIAID · NORTHWESTERN UNIVERSITY · PI MAIGA, MAMOUDOU · 2019 to 2020
$440kElucidating the molecular determinants of Henipavirus envelope-antibody and envelope-receptor interactions on viral entryF31AI154739 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OGUNTUYO, KASOPEFOLUWA Y. · 2020 to 2022
$135kBLR&D Research Career Scientist Award ApplicationIK6BX004607 · VA · JAMES J PETERS VA MEDICAL CENTER · PI HIOE, CATARINA E · 2019 to 2025
–BLRD VA I01 BX003860BLRD VA I01 BX005794BLRD VA IK6 BX004607NCATS NIH HHS UL1 TR001433NIAID NIH HHS 75N93019C00051NIAID NIH HHS F31 AI154739NIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI116851NIAID NIH HHS R01 AI123449NIAID NIH HHS R01 AI125536NIAID NIH HHS R01 AI139290NIAID NIH HHS R01 AI143839NIAID NIH HHS R21 AI148033NIAID NIH HHS R21 AI149033NIAID NIH HHS T32 AI007647
Abstract
The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous biosafety level 3 (BSL3) conditions, which limits high-throughput screening of patient and vaccine sera. Myriad BSL2-compatible surrogate virus neutralization assays (VNAs) have been developed to overcome this barrier. Yet, there is marked variability between VNAs and how their results are presented, making intergroup comparisons difficult. To address these limitations, we developed a standardized VNA using CoV2-S pseudotyped particles (CoV2pp) based on vesicular stomatitis virus bearing the
Indexed as
Antibodies, NeutralizingAntibodies, ViralCOVID-19Enzyme-Linked Immunosorbent AssayHumansNeutralization TestsSARS-CoV-2Antibodies, NeutralizingAntibodies, Viralconvalescent-phase plasmaCOVID-19neutralizing antibodiesSARS-CoV-2viral neutralization assay
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.